Search

Your search keyword '"Titorenko I"' showing total 11 results
Start Over Author "Titorenko I" Search Limiters Available in Library Collection
11 results on '"Titorenko I"'

3. PB1812 PHARMACO-ECONOMY ANALYSIS OF THE THREATMENT WITH R-DA-EPOCH, R-CHOP, AND CHOP-LIKE REGIMENS IN HIGH-RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (UKRAINIAN MULTICENTER STUDY)

Author

Filonenko, K., primary, Kriachok, I., additional, Martynchyk, A., additional, Titorenko, I., additional, Stepanischyna, Y., additional, Aleksyk, O., additional, Ulianchenko, K., additional, Pastushenko, I., additional, Kushchevyy, E., additional, Novosad, O., additional, Karnabeda, O., additional, Dyagil, I., additional, Martina, Z., additional, and Kozlov, V., additional

Published
2019
Full Text
View/download PDF

4. Ukrainian Association for helping patients with lymphoproliferative diseases: Patients support care program

Author

Kryachok, I., primary, Novosad, O., additional, Skrypets, T., additional, Kadnikova, T., additional, Titorenko, I., additional, Aleksik, O., additional, Filonenko, K., additional, Martynchyk, A., additional, Pastushenko, Y., additional, Stepanishina, Y., additional, Kushchevyy, E., additional, Ulianchenko, K., additional, Surkis, M., additional, Jurchishina, V., additional, and Gingsburg, E., additional

Published
2017
Full Text
View/download PDF

7. Results of Interim Analysis of Prospective Randomized Multicenter Open-Label Study in Comparison of Efficacy and Toxicity of Beacopp-14 and Beacopp-Esc Regimens in Patients with Hodgkin'S Lymphoma from Poor-Prognosis Group

Author

Kriachok, I., primary, Titorenko, I., additional, Novosad, O., additional, Aleksyk, O., additional, Kadnikova, T., additional, Martynchyk, A., additional, Hubareva, H., additional, Kushchevyy, E., additional, and Stepanishina, I., additional

Published
2014
Full Text
View/download PDF

8. The influence of GSTP1 A313G polymorphism on susceptibility, chemotherapy-related toxicity and prognosis of Hodgkin’s lymphoma in Ukrainian patients

Author

Kriachok, I. A., primary, Khranovska, N. M., additional, Svergun, N. M., additional, Filonenko, K. S., additional, Novosad, O. I., additional, Titorenko, I. B., additional, Martynchik, A. V., additional, Gubareva, H. O., additional, Kadnikova, T. V., additional, Aleksik, O. M., additional, Kushchevyy, E. V., additional, and Pastushenko, I. V., additional

Published
2012
Full Text
View/download PDF

11. MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis.

Author

Novosad O, Skrypets T, Pastushenko Y, Titorenko I, Martynchyk A, Skachkova O, Inomistova M, Gorbach A, Khranovska N, and Kryachok I

Subjects
Adult, Female, Humans, Male, Middle Aged, Mutation, Young Adult, GTP Phosphohydrolases genetics, Histiocytosis, Langerhans-Cell genetics, MAP Kinase Signaling System, Membrane Proteins genetics, Proto-Oncogene Proteins B-raf genetics, Proto-Oncogene Proteins p21(ras) genetics
Abstract

Background: Clinical outcomes of Langerhans cell histiocytosis (LCH) are highly variable. It has been suggested that mitogen-activated protein kinase (MAPK) /extracellular signal-regulated kinases (ERK) signaling pathway might be activated in LCH patients., Materials and Methods: We investigated KRAS, BRAF and NRAS mutations in patients with LCH by qPCR., Results: Eight adult patients with LCH were treated at the National Cancer Institute, Kiev, Ukraine. Five patients received chemo plus radiation therapy and three patients received only chemotherapy, resp. (p < 0.05). All patients received LCH-I study protocol, six cycles in average. A BRAF c.1799T > A, p. V600E mutation was detected in 25% (2/8) of cases - 1 patient had an early relapse in 6 months, and 1 patient - stable disease. We did not find any BRAF, KRAS or NRAS mutations in three patients with late relapses (in 15, 24 and 46 months). Notably, KRAS mutations were not revealed in any LCH samples. The NRAS c.182A > G, p. Q61R mutation was found in two cases - one patient had LCH transformed to Hodgkins lymphoma, one patient had a refractory disease. Time to relapse rate (TTR) in patients with and without BRAF V600E gene mutation was 13 vs. 28 months, resp. (p < 0.05). TTR was 31.3 vs. 6.41 months in patients with absence and presence of NRAS mutation, p < 0.05. Multivariate analysis showed the presence of NRAS Q61R mutation was associated with poor event-free survival in LCH patients with HR of 6.1 (95% CI 0.2-12.6; p = 0.008)., Conclusion: BRAF and NRAS mutations in LCH suggest a possibility of the disease being driven by the activation of the MAPK/ERK pathway. These oncogenic mutations provide new opportunities in understanding LCH pathogenesis and may be a potential target of therapy.Key words: Langerhans cell histiocytosis - mutations - prognostic factors - relapse - survival.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results